Navigation Links
London researchers lead innovative new cancer treatment study
Date:12/14/2011

LONDON, ON An innovative treatment technology could give cancer patients new hope for survival. In an international study based at Lawson Health Research Institute and London Health Sciences Centre's London Regional Cancer Program (LRCP), scientists are testing a therapy with the potential to eradicate cancers previously thought to be incurable.

Many complications of cancer occur when it spreads from the original tumour to other areas of the body, such as the brain, liver, or lungs. At this point, the odds of survival are low. Traditional treatments, like chemotherapy, can sometimes slow down the disease, but not stop it.

Using stereotactic ablative radiotherapy, or "SABR," scientists believe they may have found a solution. SABR delivers very large, concentrated doses of radiotherapy to very precise areas, often with few side-effects.

In the newly launched COMET Trial, Dr. David Palma and his colleagues will assess SABR's impact on patient survival, side effects, and quality of life. Over the next four years, 99 patients in Canada and Europe will be randomized to receive either the SABR treatment or the standard-of-care treatment.

"This technology holds promise, in that we are using radiation to target cancers that would previously have been considered incurable," says Dr. Palma. "Although some centres have been using SABR for this purpose with promising results, the COMET study will allow us to see if it really provides a benefit for these patients."

"This trial will help establish the safety and benefit of advanced radiation techniques for the aggressive treatment of patients with a small number of sites of cancer spread," adds Dr. Glenn Bauman, Lawson Scientist and Chair/Chief of the Department of Oncology at LRCP. "Expanding the range of treatment options available and providing better cancer control for these patients are important goals of the trial."

The COMET trial is funded by the Ontario Institute for Cancer Research. In 2012, this Lawson-led study will extend to other collaborators in Ontario, British Columbia, and the Netherlands.

Dr. David Palma is a Scientist at Lawson and a Radiation Oncologist at London Health Sciences Centre's LRCP.


'/>"/>

Contact: Sonya Gilpin
sonya.gilpin@lawsonresearch.com
519-685-8500 x75852
Lawson Health Research Institute
Source:Eurekalert

Related biology news :

1. A London effort to develop point-of-care nanosensors for HIV diagnosis and monitoring
2. Imperial College London and NTU collaborate to offer joint Ph.D. programs in engineering and science
3. Kings College London signs agreement to strengthen Brazilian research links
4. Press registration is now open for EULAR 2011, May 25-28, London
5. Researcher to present discoveries on medical uses of ultrasound to London’s Royal Society
6. Researcher to present discoveries on medical uses of ultrasound to Londons Royal Society
7. Media invitation: Pioneer of organ-on-a-chip technology to speak at Imperial College London
8. NC State researchers get to root of parasite genome
9. Researchers find animal with ability to survive climate change
10. Researchers find an essential gene for forming ears of corn
11. Researchers note differences between people and animals on calorie restriction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology: